Cell membrane-associated mineralocorticoid receptors?: New evidence

Hypertension

Volumn 57, Issue 6, 2011, Pages 1019-1025

  Krug, Alexander W ^a   Pojoga, Luminita H ^a   Williams, Gordon H ^a   Adler, Gail K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aldosterone; mineralocorticoid receptor; nongenomic effects; plasma membrane

Indexed keywords

ALDOSTERONE; ANDROGEN RECEPTOR; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; GLUCOCORTICOID RECEPTOR; INSULIN RECEPTOR; MINERALOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B;

CAVEOLA; CELL MEMBRANE; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ALDOSTERONE; ANIMALS; CELL MEMBRANE; HUMANS; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ALDOSTERONE; RECEPTORS, CELL SURFACE; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 79956364204     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.159459     Document Type: Review

References (91)

1. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005;10:7-13. (Pubitemid 40895311)
2. Moura AM, Worcel M. Direct action of aldosterone on transmembrane 22Na efflux from arterial smooth muscle: rapid and delayed effects. Hypertension. 1984;6:425-430. (Pubitemid 14091472)
3. Harvey BJ, Ehrenfeld J. Role of Na+/H+ exchange in the control of intracellular pH and cell membrane conductances in frog skin epithelium. J Gen Physiol. 1988;92:793-810. (Pubitemid 19027064)
4. Oberleithner H, Weigt M, Westphale HJ, Wang W. Aldosterone activates Na+/H+ exchange and raises cytoplasmic pH in target cells of the amphibian kidney. Proc Natl Acad Sci USA. 1987;84:1464-1468. (Pubitemid 17027375)
5. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol. 2009;308:53-62.
6. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005; 26:313-321. (Pubitemid 40686645)
7. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005;70: 347-351. (Pubitemid 40616031)
8. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227-1235. (Pubitemid 43189712)
9. Wehling M, Kasmayr J, Theisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am J Physiol. 1991;260:E719-E726.
10. Gekle M, Silbernagl S, Wunsch S. Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells. J Physiol. 1998;511:255-263. (Pubitemid 28421328)
11. Le Moellic C, Ouvrard-Pascaud A, Capurro C, Cluzeaud F, Fay M, Jaisser F, Farman N, Blot-Chabaud M. Early nongenomic events in aldosterone action in renal collecting duct cells: PKCα activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol. 2004;15:1145-1160. (Pubitemid 38525996)
12. Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev. 2007;28:726-741. (Pubitemid 350294293)
13. Stevis PE, Deecher DC, Suhadolnik L, Mallis LM, Frail DE. Differential effects of estradiol and estradiol-BSA conjugates. Endocrinology. 1999; 140:5455-5458.
14. Wildling L, Hinterdorfer P, Kusche-Vihrog K, Treffner Y, Oberleithner H. Aldosterone receptor sites on plasma membrane of human vascular endothelium detected by a mechanical nanosensor. Pflugers Arch. 2009; 458:223-230.
15. Oberleithner H, Schafer C, Shahin V, Albermann L. Route of steroid-activated macromolecules through nuclear pores imaged with atomic force microscopy. Biochem Soc Trans. 2003;31:71-75. (Pubitemid 36241399)
16. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697-1710. (Pubitemid 41007884)
17. Haseroth K, Gerdes D, Berger S, Feuring M, Gunther A, Herbst C, Christ M, Wehling M. Rapid nongenomic effects of aldosterone in mineralocorticoid- receptor-knockout mice. Biochem Biophys Res Commun. 1999;266:257-261. (Pubitemid 30028801)
18. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, Davis PJ. Integrin α Vβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005;146:2864-2871. (Pubitemid 41002793)
19. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology. 2004;145:3265-3272. (Pubitemid 38829999)
20. Zhao X, Lorenc H, Stephenson H, Wang YJ, Whitherspoon D, Katzenellenbogen B, Pfaff D, Vasudevan N. Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen response element in neuroblastoma cells. Proc Natl Acad Sci USA. 2005;102: 4890-4895. (Pubitemid 40471549)
21. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD. GPR30 expression is required for the mineralocorticoid receptor independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442-451.
22. Mihailidou AS, Buhagiar KA, Rasmussen HH. Na+ influx and Na(+)-K+ pump activation during short-term exposure of cardiac myocytes to aldosterone. Am J Physiol. 1998;274:C175-C181.
23. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology. 2005;146:973-980. (Pubitemid 40289282)
24. Mihailidou AS. Nongenomic actions of aldosterone: physiological or pathophysiological role? Steroids. 2006;71:277-280.
25. Alzamora R, Michea L, Marusic ET. Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension. 2000;35:1099-1104. (Pubitemid 30327264)
26. Grossmann C, Husse B, Mildenberger S, Schreier B, Schuman K, Gekle M. Colocalization of mineralocorticoid and EGF receptor at the plasma membrane. Biochim Biophys Acta. 2010;1803:584-590.
27. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGFreceptor signaling. Steroids. 2002;67:499-504.
28. Krug AW, Schuster C, Gassner B, Freudinger R, Mildenberger S, Troppmair J, Gekle M. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem. 2002;277:45892-45897. (Pubitemid 35417570)
29. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem. 2007;282:22278-22288. (Pubitemid 47267344)
30. Marino M, Ascenzi P. Steroid hormone rapid signaling: the pivotal role of S-palmitoylation. IUBMB Life. 2006;58:716-719. (Pubitemid 46900132)
31. Baekkeskov S, Kanaani J. Palmitoylation cycles and regulation of protein function (review). Mol Membr Biol. 2009;26:42-54.
32. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab. 2009;20:477-482.
33. Chun M, Liyanage UK, Lisanti MP, Lodish HF. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc Natl Acad Sci USA. 1994;91: 11728-11732. (Pubitemid 24356418)
34. Okamoto Y, Ninomiya H, Miwa S, Masaki T. Cholesterol oxidation switches the internalization pathway of endothelin receptor type A from caveolae to clathrin-coated pits in Chinese hamster ovary cells. J Biol Chem. 2000;275:6439-6446. (Pubitemid 30129941)
35. Yamaguchi T, Murata Y, Fujiyoshi Y, Doi T. Regulated interaction of endothelin B receptor with caveolin-1. Eur J Biochem. 2003;270: 1816-1827. (Pubitemid 36532541)
36. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG Jr, Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem. 1998;273:26962-26968. (Pubitemid 28471718)
37. Nystrom FH, Chen H, Cong LN, Li Y, Quon MJ. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol Endocrinol. 1999; 13:2013-2024. (Pubitemid 30637263)
38. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997;272: 30429-30438. (Pubitemid 27512253)
39. Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG, Lisanti MP. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem. 1999;274:33551-33556. (Pubitemid 129511665)
40. Chambliss KL, Yuhanna IS, Mineo C, Liu P, German Z, Sherman TS, Mendelsohn ME, Anderson RG, Shaul PW. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res. 2000;87:E44-E52.
41. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem. 2001;276:13442-13451.
42. Jain S, Li Y, Kumar A, Sehgal PB. Transcriptional signaling from membrane raft-associated glucocorticoid receptor. Biochem Biophys Res Commun. 2005;336:3-8. (Pubitemid 41253394)
43. Sargiacomo M, Sudol M, Tang Z, Lisanti MP. Signal transduction molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cell. J Cell Biol. 1993;122: 789-807. (Pubitemid 23241090)
44. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996;271:29182-29190. (Pubitemid 26382628)
45. Razani B, Rubin CS, Lisanti MP. Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J Biol Chem. 1999;274:26353-26360.
46. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 1998;428:205-211. (Pubitemid 28319685)
47. Zundel W, Swiersz LM, Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol. 2000;20:1507-1514. (Pubitemid 30100170)
48. Fagan KA, Smith KE, Cooper DM. Regulation of the Ca2+-inhibitable adenylyl cyclase type VI by capacitative Ca2+ entry requires localization in cholesterol-rich domains. J Biol Chem. 2000;275:26530-26537.
49. Ostrom RS, Violin JD, Coleman S, Insel PA. Selective enhancement of beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes. Mol Pharmacol. 2000;57:1075-1079. (Pubitemid 30253394)
50. Rybin VO, Xu X, Lisanti MP, Steinberg SF. Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem. 2000;275:41447-41457. (Pubitemid 32054981)
51. García-Cardeña G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA. 1996; 93:6448-6453. (Pubitemid 26230326)
52. Liu J, García-Cardeña G, Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry. 1996;35: 13277-13281. (Pubitemid 26349419)
53. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson RG, Michel T. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem. 1996;271:6518-6522. (Pubitemid 26095467)
54. Pojoga LH, Adamova Z, Kumar A, Stennett AK, Romero JR, Adler GK, Williams GH, Khalil RA. Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1 deficient mice. Am J Physiol Heart Circ Physiol. 2010;298: H1776-H1788.
55. Pojoga LH, Romero JR, Yao TM, Loutraris P, Ricchiuti V, Coutinho P, Guo C, Lapointe N, Stone JR, Adler GK, Williams GH. Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-Larginine methyl ester and angiotensin II. Endocrinology. 2010;151: 1236-1246.
56. Szego CM, Davis JS. Adenosine 3′,5′-monophosphate in rat uterus: acute elevation by estrogen. Proc Natl Acad Sci USA. 1967;58:1711-1718.
57. Pietras RJ, Szego CM. Endometrial cell calcium and oestrogen action. Nature. 1975;253:357-359.
58. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature. 1977;265:69-72. (Pubitemid 8004314)
59. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER. Identification of a structural determinant necessary for the localization and function of estrogen receptor αat the plasma membrane. Mol Cell Biol. 2003;23:1633-1646. (Pubitemid 36246045)
60. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERΒ has nongenomic action in caveolae. Mol Endocrinol. 2002;16: 938-946.
61. Frank PG, Hassan GS, Rodriguez-Feo JA, Lisanti MP. Caveolae and caveolin-1: novel potential targets for the treatment of cardiovascular disease. Curr Pharm Des. 2007;13:1761-1769. (Pubitemid 46979714)
62. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor αvariant (ER46) in human endothelial cells. Proc Natl Acad Sci USA. 2003;100:4807-4812. (Pubitemid 36457810)
63. Gaillard S, Bartoli M, Castets F, Monneron A. Striatin, a calmodulindependent scaffolding protein, directly binds caveolin-1. FEBS Lett. 2001;508:49-52. (Pubitemid 33055665)
64. Castets F, Bartoli M, Barnier JV, Baillat G, Salin P, Moqrich A, Bourgeois JP, Denizot F, Rougon G, Calothy G, Monneron A. A novel calmodulin-binding protein, belonging to the WD-repeat family, is localized in dendrites of a subset of CNS neurons. J Cell Biol. 1996;134: 1051-1062. (Pubitemid 26278227)
65. Lu Q, Surks HK, Ebling H, Baur WE, Brown D, Pallas DC, Karas RH. Regulation of estrogen receptorα-mediated transcription by a direct interaction with protein phosphatase 2A. J Biol Chem. 2003;278: 4639-4645. (Pubitemid 36800962)
66. Benoist M, Gaillard S, Castets F. The striatin family: a new signaling platform in dendritic spines. J Physiol Paris. 2006;99:146-153.
67. Greger JG, Fursov N, Cooch N, McLarney S, Freedman LP, Edwards DP, Cheskis BJ. Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. Mol Cell Biol. 2007;27:1904-1913.
68. Balasenthil S, Vadlamudi RK. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem. 2003;278:22119-22127. (Pubitemid 36792622)
69. Cheskis BJ, Greger J, Cooch, McNally C, McLarney S, Lam HS, Rutledge S, Mekonnen B, Hauze D, Nagpal S, Freedman LP. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids. 2008;73:901-905.
70. Savkur RS, Burris TP. The coactivator LXXLL nuclear receptor recognition motif. J Pept Res. 2004;63:207-212. (Pubitemid 38496672)
71. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M. Palmitoylation-dependent estrogen receptor αmembrane localization: regulation by 17β-estradiol. Mol Biol Cell. 2005;16:231-237. (Pubitemid 40028339)
72. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol. 2002;16:100-115. (Pubitemid 34044501)
73. Levin ER. Rapid signaling by steroid receptors. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1425-R1430.
74. Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science. 1991;252:1848-1851. (Pubitemid 21917109)
75. Gametchu B, Chen F, Sackey F, Powell C, Watson CS. Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Steroids. 1999;64:107-119. (Pubitemid 29168594)
76. Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, Bienert M, Radbruch A, Burmester GR, Lauster R, Scheffold A, Buttgereit F. Membrane glucocorticoid receptors can be detected in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J. 2004;18:70-80. (Pubitemid 38076467)
77. Spies CM, Schaumann DH, Berki T, Mayer K, Jakstadt M, Huscher D, Wunder C, Burmester GR, Radbruch A, Lauster R, Scheffold A, Buttgereit F. Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway, Ann Rheum Dis. 2006;65: 1139-1146. (Pubitemid 44277386)
78. Buttgereit F, Saag KG, Cutolo M, da Silva JA, Bijlsma JW. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005;34:14-21. (Pubitemid 40445053)
79. Lowenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, van Deventer SJ, Hommes DW. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep. 2006;7:1023-1029. (Pubitemid 44480518)
80. Solito E, Mulla A, Morris JF, Christian HC, Flower RJ, Buckingham JC. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, proteinkinase C, phophatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology. 2003;144:1164-1174. (Pubitemid 36428456)
81. Freeman MR, Cinar B, Kim J, Kim J, Mukhopadhyah NK, Cinar B, Lutchman M, Richie JP, Freeman MR, Liu BC. Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids. 2007;72:210-217. (Pubitemid 46273499)
82. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 2004; 64:7156-7168. (Pubitemid 39331031)
83. Cheng J, Watkins SC, Walker WH. Testosterone activates mitogen-activated protein kinase via Src kinase and the epidermal growth factor receptor in sertoli cells. Endocrinology. 2007;148:2066-2074. (Pubitemid 46997076)
84. Karteris E, Zervou S, Pang Y, Dong J, Hillhouse EW, Randeva HS, Thomas P. Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol. 2006;20:1519-1534. (Pubitemid 43967561)
85. Baldi E, Luconi M, Muratori M, Marchiani S, Tamburrino L, Forti G. Nongenomic activation of spermatozoa by steroid hormones: facts and fictions. Mol Cell Endocrinol. 2009;308:39-46.
86. Engmann L, Losel R, Wehling M, Peluso JJ. Progesterone regulation of human granulosa/luteal cell viability by an RU486-independent mechanism. J Clin Endocrinol Metab. 2006;91:4962-4968. (Pubitemid 44917335)
87. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell. 2001;8:269-280. (Pubitemid 32831545)
88. Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP. The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene 88 and cell cycle progression. Steroids. 2008;73:922-928.
89. Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, Lange CA. Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids. 2007;72:188-201. (Pubitemid 46273495)
90. Lange CA. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol. 2004;18:269-278. (Pubitemid 38183927)
91. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol. 2007;27:466-480. (Pubitemid 46080117)